## N A Mark Estes Iii

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5010679/publications.pdf

Version: 2024-02-01

100 papers 8,629 citations

236925 25 h-index 72 g-index

101 all docs

 $\begin{array}{c} 101 \\ \\ \text{docs citations} \end{array}$ 

101 times ranked

7086 citing authors

#	Article	IF	CITATIONS
1	EP News Clinical February 2022. Heart Rhythm, 2022, , .	0.7	O
2	EP News Clinical April 3, 2022. Heart Rhythm, 2022, , .	0.7	O
3	Impact of an Automated Best Practice Alert on Sex and Race Disparities in Implantable Cardioverterâ€Defibrillator Therapy. Journal of the American Heart Association, 2022, 11, e023669.	3.7	4
4	Predictors of Hospital Admissions for Ventricular Arrhythmia or Cardiac Arrest in Patients With Cardiomyopathy. American Journal of Cardiology, 2022, 171, 127-131.	1.6	1
5	EP News Clinical May 2022. Heart Rhythm, 2022, , .	0.7	O
6	EP News Clinical June 2022. Heart Rhythm, 2022, , .	0.7	0
7	EP News Clinical July 2022. Heart Rhythm, 2022, , .	0.7	O
8	Ablation of Atrial Fibrillation in Hypertrophic Cardiomyopathy: Semper Discere (Always Learning). Journal of the American Heart Association, 2021, 10, e019876.	3.7	2
9	Exercise and Athletic Activity in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 173-182.	1.7	1
10	Inverse association of mortality and body mass index in patients with left ventricular systolic dysfunction of both ischemic and ⟨scp⟩nonâ€ischemic⟨/scp⟩ etiologies. Clinical Cardiology, 2021, 44, 495-500.	1.8	3
11	Cardiac Magnetic Resonance Imaging in Nonischemic Cardiomyopathy. Circulation, 2021, 143, 1374-1376.	1.6	1
12	Outcomes of Blacks Versus Whites with Cardiomyopathy. American Journal of Cardiology, 2021, 148, 151-156.	1.6	2
13	Response by Alyesh et al to Letter Regarding Article, "A Blueprint for Productive Maintenance of Certification, but Is the American Board of Internal Medicine up to the Challenge?― Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007961.	2.2	O
14	Ventricular pacing and myocardial function in patient with congenital heart block. Journal of Cardiovascular Electrophysiology, 2021, 32, 2684-2689.	1.7	3
15	EP News Clinical November 2021. Heart Rhythm, 2021, , .	0.7	O
16	Atrial Resynchronization Therapy: An Emerging Potential to Advance Physiologic Pacing?. Heart Rhythm, 2021, , .	0.7	0
17	Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. American Journal of Cardiology, 2020, 125, 210-214.	1.6	39
18	Impact of Lifestyle Modification on Atrial Fibrillation. American Journal of Cardiology, 2020, 125, 289-297.	1.6	27

#	Article	IF	CITATIONS
19	Improving outcomes after left atrial appendage closure. Heart Rhythm, 2020, 17, 734-735.	0.7	0
20	Documentation of shared decision making around primary prevention defibrillator implantations. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 100-109.	1.2	2
21	Risk Factor Modification for AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2020, 6, 1288-1290.	3.2	0
22	Mobile cardiac monitoring during the COVIDâ€19 pandemic: Necessity is the mother of invention. Journal of Cardiovascular Electrophysiology, 2020, 31, 2812-2813.	1.7	3
23	Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008123.	4.8	21
24	Primary prevention of sudden death with the implantable cardioverter defibrillator: bridging the evidence gap. European Heart Journal, 2020, 41, 3448-3450.	2.2	5
25	Impact of Diabetes Mellitus on Mortality and Hospitalization in Patients With Mild-to-Moderate Cardiomyopathy. JACC: Clinical Electrophysiology, 2020, 6, 552-558.	3.2	4
26	Improving Outcomes in Patients With Atrial Fibrillation and Hypertension. JAMA - Journal of the American Medical Association, 2020, 323, 221.	7.4	2
27	Priority plan for invasive cardiac electrophysiology procedures during the coronavirus disease 2019 (COVIDâ€19) pandemic. Journal of Cardiovascular Electrophysiology, 2020, 31, 1255-1258.	1.7	6
28	A Blueprint for Productive Maintenance of Certification, But Is the American Board of Internal Medicine up to the Challenge?. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006696.	2.2	1
29	Implications of Neurological Status on Defibrillator Therapy and Long-Term Mortality of Sudden Cardiac Arrest Survivors. JACC: Clinical Electrophysiology, 2019, 5, 843-850.	3.2	0
30	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.7	135
31	Prediction and Prevention of Sudden Death in the Brugada Syndrome. American Journal of Cardiology, 2019, 124, 1797-1802.	1.6	1
32	In replyâ€"Atrial Fibrillation and Morbidity and Mortality in Stress-Induced Cardiomyopathy. Mayo Clinic Proceedings, 2019, 94, 2148-2149.	3.0	0
33	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.7	494
34	MY APPROACH to Commotio Cordis. Trends in Cardiovascular Medicine, 2019, 29, 248.	4.9	0
35	Trends and Implications of DF-4 Implantable Cardioverter-Defibrillator Lead Adoption in the United States of America. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007134.	4.8	4
36	Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 123, 1859-1862.	1.6	24

3

#	Article	IF	CITATIONS
37	Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field?. American Journal of Cardiology, 2018, 121, 1008-1010.	1.6	13
38	Class IC antiarrhythmic agents in structural heart disease: Is nothing CAST in stone?. Heart Rhythm, 2018, 15, 164-165.	0.7	0
39	Defibrillation threshold testing in hypertrophic cardiomyopathy: As SIMPLE as possible but not simpler. Heart Rhythm, 2018, 15, 393-394.	0.7	1
40	His bundle pacing. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 323-334.	1.3	3
41	Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 1862-1865.	1.6	34
42	In Replyâ€"Atrial Fibrillation: Interatrial Block May Be an Underdiagnosed and Easily Recognizable Risk Factor. Mayo Clinic Proceedings, 2017, 92, 682.	3.0	0
43	Atrial Fibrillation in Athletes. JACC: Clinical Electrophysiology, 2017, 3, 921-928.	3.2	35
44	Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 2017, 136, 2420-2436.	1.6	183
45	Prediction and Prevention of Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 631-638.	1.7	26
46	Sudden Cardiac Death: Contemporary Challenges. Cardiac Electrophysiology Clinics, 2017, 9, xvii-xviii.	1.7	0
47	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. Circulation, 2017, 135, 2310-2312.	1.6	107
48	Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: Findings from the North American ARVC Registry. Journal of Cardiovascular Electrophysiology, 2016, 27, 555-562.	1.7	37
49	Stroke Risk Stratification in Atrial Fibrillation: Bridging the Evidence Gaps. Journal of Cardiovascular Electrophysiology, 2016, 27, 271-273.	1.7	4
50	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	1.5	24
51	Clinical Outcomes of Patients Who Received the Subcutaneous Implantable Cardioverter Defibrillator. JAMA Cardiology, 2016, 1, 861.	6.1	1
52	The State of the Art. Mayo Clinic Proceedings, 2016, 91, 1778-1810.	3.0	154
53	Impact of generator replacement on the risk of Fidelis lead fracture. Heart Rhythm, 2016, 13, 1618-1623.	0.7	3
54	Response to Letter Regarding Article, "Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement― Circulation, 2016, 133, e437-8.	1.6	1

#	Article	IF	CITATIONS
55	Left Atrial Appendage Closure for Stroke Prevention in AF. Journal of the American College of Cardiology, 2015, 66, 2740-2742.	2.8	1
56	Advances in the Prevention and Treatment of Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 103-104.	3.1	5
57	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects. Circulation, 2015, 132, e315-25.	1.6	114
58	Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. European Heart Journal, 2015, 36, ehv162.	2.2	171
59	Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2015. 36. 1735-1743.	2.2	236
60	Cardiac Resynchronization Therapy forÂMild Heart Failure. JACC: Heart Failure, 2015, 3, 701-702.	4.1	0
61	Should Preparticipation Cardiovascular Screening of Athletes Include ECG? No: There Is Not Enough Evidence to Support Including ECG in the Preparticipation Sports Evaluation. American Family Physician, 2015, 92, 343-4.	0.1	2
62	Following leads to improve patient outcomes: It's about time. Heart Rhythm, 2014, 11, 2163-2164.	0.7	1
63	Evaluation and Management of Heart Rhythm Disturbances Due to Cardiac Sarcoidosis. Heart Lung and Circulation, 2014, 23, 1100-1109.	0.4	9
64	Examining Achilles' Heel. JACC: Cardiovascular Imaging, 2014, 7, 1249-1250.	5.3	2
65	Advances in Sudden Death Prevention: The Emerging Role of a Fully Subcutaneous Defibrillator. American Journal of Medicine, 2014, 127, 188-194.	1.5	10
66	The Disconnect Between the Guidelines, the Appropriate Use Criteria, and Reimbursement Coverage Decisions. Journal of the American College of Cardiology, 2014, 63, 12-14.	2.8	28
67	Ventricular Arrhythmias in the North American Multidisciplinary Study of ARVC. Journal of the American College of Cardiology, 2014, 64, 119-125.	2.8	156
68	Is it Time for a New Approach to Implantable Cardioverter-Defibrillator Replacement?â^—. Journal of the American College of Cardiology, 2014, 63, 2395-2397.	2.8	5
69	Mayo Clinic Electrophysiology ManualAsirvathamSamuel J., Ed. 711 pages. Oxford, UK: Oxford University Press, 2013. \$147.98. ISBN:13 978-0199941193. Circulation, 2014, 129, 1992-1993.	1.6	0
70	EP News: Clinical. Heart Rhythm, 2013, 10, 1247.	0.7	0
71	Agreement Between <scp>ICU</scp> Clinicians and Electrophysiology Cardiologists on the Decision to Initiate a <scp>QT</scp> câ€interval Prolonging Medication in Critically III Patients with Potential Risk Factors for Torsade de Pointes: A Comparative, Caseâ€Based Evaluation. Pharmacotherapy, 2013, 33, 589-597.	2.6	10
72	Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine, 2012, 367, 2275-2283.	27.0	1,186

#	Article	IF	CITATIONS
73	Ablation of Atrial Flutter in Severe Pulmonary Hypertension: Pushing the Outside of the Envelope. Journal of Cardiovascular Electrophysiology, 2012, 23, 1191-1192.	1.7	3
74	Preparticipation Athletic Screening Including an Electrocardiogram: An Unproven Strategy for Prevention of Sudden Cardiac Death in the Athlete. Progress in Cardiovascular Diseases, 2012, 54, 451-454.	3.1	24
75	Incidence and Significance of Pacemaker and Implantable Cardioverterâ€Defibrillator Lead Masses Discovered during Transesophageal Echocardiography. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 679-683.	1.2	68
76	Interdisciplinary strategies for arrhythmia program development: measuring quality, performance, and outcomes. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 91-99.	1.3	1
77	Predicting and Preventing Sudden Cardiac Death. Circulation, 2011, 124, 651-656.	1.6	55
78	Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. New England Journal of Medicine, 2009, 361, 1329-1338.	27.0	2,716
79	Clinical. Heart Rhythm, 2009, 6, 1542.	0.7	0
80	Cardiac Safety of Electrical Stun Guns: Letting Science and Reason Advance the Debate. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 395-397.	1.2	11
81	Cell Membrane Stretch and Chest Blowâ€Induced Ventricular Fibrillation: Commotio Cordis. Journal of Cardiovascular Electrophysiology, 2008, 19, 1304-1309.	1.7	33
82	Commotio Cordis?Sudden Cardiac Death with Chest Wall Impact. Journal of Cardiovascular Electrophysiology, 2007, 18, 115-122.	1.7	82
83	Curing atrial fibrillation: Two decades of progress. Journal of Interventional Cardiac Electrophysiology, 2007, 20, 127-131.	1.3	5
84	Discrimination When Dual-Chamber Termination Fails: A New Paradigm for ICDs?. Journal of Cardiovascular Electrophysiology, 2006, 17, 702-704.	1.7	0
85	Automated External Defibrillators in the Public Domain. Circulation, 2005, 112, e349-51.	1.6	3
86	Task Force 7: Arrhythmias. Journal of the American College of Cardiology, 2005, 45, 1354-1363.	2.8	192
87	Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. New England Journal of Medicine, 2004, 350, 2151-2158.	27.0	1,840
88	Use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure. American Journal of Cardiology, 2003, 91, 45-52.	1.6	15
89	Predictors and Clinical Impact of Atrial Fibrillation After Pacemaker Implantation in Elderly Patients Treated with Dual Chamber Versus Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2000-2007.	1.2	44
90	Assessment of risk for sudden cardiac death. Current Problems in Cardiology, 2002, 27, 246-266.	2.4	1

#	Article	IF	CITATIONS
91	Selective Activation of the K <sup>+</sup> <sub>ATP</sub> Channel Is a Mechanism by Which Sudden Death Is Produced by Low-Energy Chest-Wall Impact (Commotio Cordis). Circulation, 1999, 100, 413-418.	1.6	135
92	Molecular biology of human arrhythmias: implications for the clinical electrophysiologist., 1998, 2, 321-324.		1
93	Inappropriate Shocks and Elevation of Defibrillation Thresholds in a Patient with Automatic Defibrillator Patch Silastic Erosion and Titanium Mesh Fraying. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1452-1455.	1.2	6
94	Apical hypertrophic cardiomyopathy presenting with sustained monomorphic ventricular tachycardia and electrocardiographic changes simulating coronary artery disease and left ventricular aneurysm. Clinical Cardiology, 1990, 13, 885-887.	1.8	25
95	Pacemakers and Exercise Current Status, Future Developments and Practical Implications of Physiological Pacemakers. Sports Medicine, 1989, 8, 1-8.	6.5	22
96	Electroanatomical Mapping of a Left-Sided Atrial Tachycardia., 0,, 59-60.		0
97	Scar-Related Intraatrial Reentrant Tachycardia. , 0, , 99-101.		O
98	Right Ventricular Outflow Tachycardia. , 0, , 163-164.		0
99	Voltage Mapping of the Right Ventricle in Arrythmogenic Right Ventricular Dysplasia. , 0, , 189-190.		O
100	Substrate Modification in Hemodynamically Unstable Infarct-Related Ventricular Tachycardia. , 0, , 229-231.		O